
ASX Announcement and Media Release

15 February, 2005

SciGen Limited

SciGen's Hepatitis B vaccine enters European market

The Directors of SciGen Limited ("SciGen" or the "Company") are pleased to announce that the Company has entered into an agreement with leading European biotechnology company Berna Biotech AG ("Berna") to be SciGen's exclusive distributor for Sci-B-VacTM in Western Europe. SciGen's entry into the European market has been made possible as a consequence of SciGen acquiring worldwide rights to Sci-B-VacTM, its third generation hepatitis B vaccine.

The Commercialisation Agreement (the "Agreement") between SciGen and Berna comprehends annual minimum orders by Berna over an initial five year term generating significant revenues for the Company. The Agreement provides for automatic renewals, with a 1 year notice period for termination. The product will be marketed in Europe under the brand name HepimmuneTM.

The cost to SciGen of acquiring the European marketing rights will be absorbed into the selling price of the vaccine into Europe over the Agreement term, with no negative impact on SciGen's current cash reserves. Sales by SciGen to Berna will be profitable. SciGen will work closely with Berna to secure regulatory approval for marketing from EMEA, the regulatory body that covers all EU countries.

SciGen's Managing Director, Mark Compton said, "This transaction again demonstrates the marketability of SciGen's products across the globe. The market of Western Europe is one of the principal pharmaceutical markets in the world and our partner Berna, has a very well established presence and high credibility in that market, particularly in the area of vaccines. Berna clearly recognises the superior quality of Sci-B-VacTM and that there is a substantial market opportunity for such a vaccine in Europe".

“This is the first expansion of SciGen’s activity outside of the Asia Pacific Region. Developing partnerships with Bioton, Berna, Intercell and others, mean the Company will continue to examine other opportunities to grow its presence over time in major markets such as Europe” Mr Compton said.

About Berna

Berna Biotech is a publicly listed Swiss biopharmaceutical company with expertise across a range of vaccines, including hepatitis B vaccine. Berna has a market capitalisation of approximately \$A430M and annual sales for FY2004 of approximately \$A75M. In FY2004 Berna sold over \$US50M in hepatitis B and paediatric vaccines. The estimated size of the hepatitis B vaccine global market is estimated to be in the order of US\$1 billion. More information on Berna can be found at www.bernabiotech.com.

About SciGen

SciGen Ltd is a biopharmaceutical company essentially involved in commercialising later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which can allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices also in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland, Switzerland, Austria and the Netherlands.

=====ENDS=====

Media enquiries

Mark Compton

Managing Director & CEO: Telephone: +61 2 9234 1700: Web: www.scigen.com.au